ENXTPA:IPNPharmaceuticals
Ipsen (ENXTPA:IPN) Stock Faces A Valuation Riddle After Strong H1 Growth
The Ipsen stock has barely budged over the past month, yet the new earnings drop a much louder hint than the share price suggests. At the heart of this half year update sits one issue that long term investors cannot ignore. The valuation is rich on a P/E of 26.7x, while a discounted cash flow model points to an intrinsic value far above the current €167.2 price. That spread, paired with a higher net profit margin and a one off loss still hanging over trailing results, sets up a clear tension...